Cystatin C standardization decreases assay variation and improves assessment of glomerular filtration rate

Abstract

BackgroundCystatin C is increasingly used in glomerular filtration rate (GFR) estimation equations. The dependence of cystatin C results upon the analytical method has been a major source of controversy. MethodsCystatin C was measured with non-standardized turbidimetric Roche Generation 1 and standardized nephelometric Siemens assays in 3666 and additionally with standardized Roche Generation 2 and Siemens in 567 blood samples of the Berlin Initiative Study. Cystatin C-based GFR was assessed with CKD-EPIcys (Chronic Kidney Disease Epidemiology) and CAPA (Caucasian, Asian, Pediatric, Adult) equations and the impact of the assays on GFR estimation was determined. Equation performance compared to measured GFR was evaluated. ResultsConcordance of Roche Gen2 and Siemens was high with median difference of 0.003±0.13mg/L (limits of agreement: −0.12 to 0.12) and Passing Bablok correlation was essentially perfect. Roche Gen1 assay showed worse concordance with Siemens: median difference was 0.08±0.13mg/L (limits of agreement: −0.18 to 0.34) and correlation was inferior. Mean difference (±SD) of estimated GFRCKD-EPIcys was 0±4mL/min/1.73m2 for Gen2 and Siemens compared to −5±8 with Gen1. Performance of GFR estimating equations was not influenced by the choice of Siemens or Gen2 assays. ConclusionsStandardization of Roche Gen2 assay improved accuracy of cystatin C measurement compared to Siemens. It suggests only negligible method bias and results in equal performance of both assays when estimating GFR indicating that successful calibration has led to major progress in cystatin C analysis.